- Home
- PLRX vs CRMD Comparison
PLRX vs CRMD Comparison
Compare PLRX & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLRX
- CRMD
- Stock Information
- Founded
- PLRX 2015
- CRMD 2006
- Country
- PLRX United States
- CRMD United States
- Employees
- PLRX N/A
- CRMD N/A
- Industry
- PLRX Biotechnology: Pharmaceutical Preparations
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- PLRX Health Care
- CRMD Health Care
- Exchange
- PLRX Nasdaq
- CRMD Nasdaq
- Market Cap
- PLRX 84.7M
- CRMD 973.3M
- IPO Year
- PLRX 2020
- CRMD 2010
- Fundamental
- Price
- PLRX $1.29
- CRMD $11.62
- Analyst Decision
- PLRX Hold
- CRMD Strong Buy
- Analyst Count
- PLRX 10
- CRMD 7
- Target Price
- PLRX $9.79
- CRMD $17.33
- AVG Volume (30 Days)
- PLRX 1.5M
- CRMD 2.5M
- Earning Date
- PLRX 08-06-2025
- CRMD 08-13-2025
- Dividend Yield
- PLRX N/A
- CRMD N/A
- EPS Growth
- PLRX N/A
- CRMD N/A
- EPS
- PLRX N/A
- CRMD 0.28
- Revenue
- PLRX N/A
- CRMD $82,553,827.00
- Revenue This Year
- PLRX N/A
- CRMD $238.38
- Revenue Next Year
- PLRX N/A
- CRMD $53.52
- P/E Ratio
- PLRX N/A
- CRMD $41.86
- Revenue Growth
- PLRX N/A
- CRMD N/A
- 52 Week Low
- PLRX $1.10
- CRMD $3.61
- 52 Week High
- PLRX $16.10
- CRMD $17.43
- Technical
- Relative Strength Index (RSI)
- PLRX 38.40
- CRMD 39.52
- Support Level
- PLRX $1.13
- CRMD $12.14
- Resistance Level
- PLRX $1.43
- CRMD $17.43
- Average True Range (ATR)
- PLRX 0.11
- CRMD 0.69
- MACD
- PLRX -0.01
- CRMD -0.51
- Stochastic Oscillator
- PLRX 21.68
- CRMD 4.60
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.